Feed / RXRX

Recursion Pharmaceuticals, Inc.

RXRX

Healthcare · 3.16 -1.6% today

Participation confirmed · construction unavailableMarket checked 10 Sept, 15:55 GMT-4

Market read

Recursion Pharmaceuticals, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 5 of 35 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 11 directly disclosed connections are confirming.

Company-1.6% todayVolume comparison unavailable
Market group5 of 35 activeSoftware Stocks · inactive
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 23 of 35 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ASAN begins moving with the group.

Invalidation: The live read weakens if participation falls to 12 of 35 members or fewer.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 5 of 35 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 11 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • At least 23 of 35 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ASAN begins moving with the group.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations319
Usable filing statements64
Verified relationships12
Evidence supporting the case
  • Latest annual revenue changed +26.9% year over year.
Evidence challenging the case
  • Operating margin changed -53.8 percentage points in the latest annual period.
  • Net margin changed -75.3 percentage points in the latest annual period.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
  • EV/sales is 57% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

3.16
6m-13.9%12m-35.4%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$10.2M+156.9%$-1.49
2022-12-31$39.8M+291.5%$-1.36+40.0%
2023-12-31$44.6M+11.9%$-1.58+18.4%
2024-12-31$58.8M+32.0%$-1.69+31.9%
2025-12-31$74.7M+26.9%$-1.44

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dmixed · 4 filings
Cash used by operating activities increased during the three months ended March 31, 2025 as a result of higher costs incurred for research and development and general and administrative primarily due to the Company’s acquisition of Exscientia.
10-Q · May 6, 2026
Restructuring and cost reductionsnegative · 2 filings
For the three months ended March 31, 2026, the decrease relative to the three months ended March 31, 2025, was primarily driven by a decrease in salaries of $6.7 million as a result of headcount reductions in the year, in addition to one-time transaction cost…
10-Q · May 6, 2026
Credit and interest ratesnegative · 1 filings
Other Income (Loss), Net The following table summarizes our components of other income (loss), net: (in thousands, except percentages) Three months ended June 30, Change Six months ended June 30, Change 2025 2024 $ % 2025 2024 $ % Interest income 5,443 3,266…
10-Q · Aug 5, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales 18.9× · EV/sales 9.0×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

3.16-1.6% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for RXRX. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for RXRX. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind RXRX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRKMerck & Co., Inc.partnerMay 6, 2026

Merck KGaA, Darmstadt, Germany Research Collaboration Agreement In September 2023, we entered into a Research Collaboration Agreement, or the RCA, with the Healthcare Business of Merck KGaA, Darmstadt, Germany, referred to as Merck KGaA, Darmstadt, Germany, p…

SNYSanofipartnerMay 6, 2026

In AI-enabled chemistry, Sanofi and Recursion joint programs continue progressing toward development candidate designation and earlier-stage milestones over the next 12 months, including programs designed against challenging targets in immunology and oncology.

Depended on by

RLYBRallybio CorporationinvesteeMar 16, 2026

In July 2025, the Company entered into a definitive agreement to sell its interest in REV102, an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 ("ENPP1") inhibitor in preclinical development for the treatment of patients with hypophosphatasia ("HPP"), to…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

RXRX is currently a Participant in the organic co-movement group Software Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.